

First demonstration of the circulation of a pneumovirus in French pigs by detection of anti-swine orthopneumovirus nucleoprotein antibodies

Charles-Adrien Richard, Caroline Hervet, Déborah Ménard, Irina Gutsche, Valérie Normand, Fanny Renois, François Meurens, Jean Francois Eléouët

To cite this version:

Charles-Adrien Richard, Caroline Hervet, Déborah Ménard, Irina Gutsche, Valérie Normand, et al.. First demonstration of the circulation of a pneumovirus in French pigs by detection of anti-swine orthopneumovirus nucleoprotein antibodies. BMC Veterinary Research, 2018, 49 (1), 10.1186/s13567- $018-0615-x$, hal-01964289

HAL Id: hal-01964289 <https://hal.science/hal-01964289>

Submitted on 21 Dec 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

[Distributed under a Creative Commons Attribution 4.0 International License](http://creativecommons.org/licenses/by/4.0/)

RESEARCH ARTICLE

First demonstration of the circulation of a pneumovirus in French pigs by detection of anti-swine orthopneumovirus nucleoprotein antibodies

Charles-Adrien Richard^{1†}, Caroline Hervet^{2†}, Déborah Ménard², Irina Gutsche³, Valérie Normand⁴, Fanny Renois², François Meurens² and Jean-François Eléouët^{1[*](http://orcid.org/0000-0002-7361-4885)}

Abstract

The presence of pneumoviruses in pigs is poorly documented. In this study, we used the published sequence of the nucleoprotein (N) of the recently identifed Swine *Orthopneumovirus* (SOV) to express and purify SOV N as a recombi‑ nant protein in *Escherichia coli*. This protein was purified as nanorings and used to set up an enzyme-linked immunosorbent assay, which was used to analyse the presence of anti-pneumovirus N antibodies in swine sera. Sera collected from diferent pig farms in the West of France and from specifc pathogen free piglets before colostrum uptake showed indirectly that a pneumovirus is circulating in pig populations with some variations between animals. Piglets before colostrum uptake were sero-negative for anti-pneumovirus antibodies while most of the other pigs showed positivity. Interestingly, in two farms presenting respiratory clinical signs and negative or under control for some com‑ mon respiratory pathogens, pigs were detected positive for anti-pneumovirus antibodies. Globally, anti-pneumovirus N antibody concentrations were variable between and within farms. Further studies will aim to isolate the circulating virus and determine its potential pathogenicity. SOV could potentially become a new member of the porcine respira‑ tory complex, important on its own or in association with other viral and bacterial micro-organisms.

Introduction

Recently, the former paramyxoviral subfamily *Pneumovirinae* was elevated to family status *Pneumoviridae* [1–3]. This new family is composed of the two genus *Metapneumovirus* and *Orthopneumovirus*. Seven diferent viruses have been identifed in several animal species as belonging to this family: avian metapneumovirus (AMPV) and human metapneumovirus (HMPV) for the *Metapneumovirus* genus, bovine respiratory syncytial virus (BRSV), ovine respiratory syncytial virus (ORV), human respiratory syncytial virus (HRSV), pneumonia virus of mice

*Correspondence: Jean‑francois.eleouet@inra.fr

Full list of author information is available at the end of the article

(PVM), and canine pneumovirus (CPV) for the *Orthopneumovirus* genus. More recently, an eighth pneumovirus was identifed by metagenomic sequencing of pooled nasal swabs in feral swine in the USA $[4]$. This newly identifed *Orthopneumovirus* shows 93% and 91% protein identities with PVM and CPV, respectively, and was named swine *Orthopneumovirus* (SOV). Since no specifc enzyme-linked immunosorbent assay (ELISA) is available for SOV, based on the close genetic relationship between PVM and SOV Hause et al. used a commercial ELISA to detect antibodies to PVM and found that 31% of the analysed feral swine sera were antibody positive [4]. Finally, analyses by the same PVM ELISA of sera from diferent American farms revealed that sera were 33% to 93% positive, dependent on the farms, and confrmed that SOV is also present in domestic swine. Interestingly, using bovine respiratory syncytial virus antigens, in 1998 Allan

© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License [\(http://creativecommons.org/licenses/by/4.0/\)](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/](http://creativecommons.org/publicdomain/zero/1.0/) [publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated.

[†] Charles-Adrien Richard and Caroline Hervet contributed equally to this work

¹ Unité de Virologie et Immunologie Moléculaires, INRA, Université Paris-Saclay, 78350 Jouy-en-Josas, France

et al. found that 41% of pigs sera from 61 herds in Northern Ireland were reactive with BRSV antigens [5].

Although SOV has not yet been isolated, the complete genomic sequence of SOV (strain 57) is available (Gen-Bank accession number: KX364383.1). We thus used the published sequences to synthesize expression vectors for nucleoprotein (N) and phosphoprotein (P) in order to express these proteins in bacteria. As developed previously with HRSV [6], co-expression of the C-terminal region of SOV P fused to GST together with SOV N allowed us to purify SOV N nanorings. These N nanorings were used further to develop an ELISA in order to detect the presence of anti-pneumovirus N antibodies in domestic pigs in the West of France.

Materials and methods

Expression and purifcation of recombinant SOV nucleoprotein

The full-length SOV N and P coding sequences (Gen-Bank accession number: KX364383.1) were synthesized for optimized expression in *Escherichia coli* (Genscript). Our previous studies with respiratory syncytial virus showed that the P C-terminal disordered region (PCT, amino acid residues 161–241, Figure 1) fused to GST is very efficient for purifying HRSV N protein after co-expression in E . *coli* [6]. The same approach was applied to SOV. First, the C-terminal disordered region of SOV P (amino acid residues 208–295) was determined by alignment with HRSV P (Figure 1).

The identified region of SOV P was amplified by PCR and subcloned in pGEX-4T-3 at BamHI-XhoI sites to engineer the pGEX-PCT vector. SOV N gene was subcloned in pET28a+ at NdeI-XhoI sites to engineer the pET-N vector. *E. coli* BL21 (DE3) (Novagen) cells were co-transformed with the pGEX-PCT and pET-N plasmids and were grown at 37 °C for 8 h in 1 L of Luria– Bertani (LB) medium containing 100 µg/mL ampicillin and 50 μ g/mL kanamycin. The same volume of fresh LB was then added, and protein expression was induced by adding isopropyl-ß-D-thio-galactoside (IPTG) to the medium (fnal concentration 0.33 mM). Bacteria were grown at 28 °C and harvested by centrifugation 15 h after induction. Bacterial pellets were re-suspended in lysis bufer (50 mM Tris–HCl pH 7.8, 60 mM NaCl, 1 mM EDTA, 2 mM DTT, 0.2% Triton X-100, 1 mg/L lysozyme) supplemented with complete protease inhibitor cocktail (Roche, Mannheim, Germany) and incubated for 1 h on ice, sonicated, and centrifuged at 4 °C for 30 min at 10 000 \times *g*. Glutathione-Sepharose 4B beads (GE Healthcare, Uppsala, Sweden) were added to clarifed supernatants and incubated at 4 °C for 15 h. Beads were then washed two times in lysis buffer and three times in PBS 1X, then stored at 4 °C in an equal volume of PBS. To isolate PCT-N complexes, beads were resuspended in an equal volume of $PBS + 1$ mM DTT and incubated with biotinylated thrombin (Novagen) for 16 h at 20 $°C$. Thrombin was then removed using the Thrombin cleavage capture kit according to

the manufacturer's instructions (Novagen). Purifed complexes were run in polyacrylamide gels stained with Coomassie blue.

Negative stain electron microscopy observations of recombinant SOV nucleoprotein

Three microliter of sample were applied to the clean side of carbon on a carbon–mica interface and stained with 2% sodium silicotungstate. Micrographs were recorded on a FEI Tecnai T12 microscope operated at 120 kV with a Gatan Orius 1000 camera. Images were recorded at a nominal magnification of 23 $000 \times$ resulting in a pixel size of 2.8 Å.

Serum samples

Positive standards: Sera obtained from diferent pig farms located in the West of France were used to search for positive reactions to SOV nucleoprotein. Sera with an optical density (OD) superior to 3.5 were selected as positive standards. Amongst these sera, one with intermediate OD was used to make serial dilutions (1/50, 1/75,

1/100, 1/200, 1/400, 1/800, 1/600, 1/3200, and 1/6400) and generate a standard curve. Then, two additional sera with extremely high OD were also assessed to generate potential standard curves.

Negative standards

Sera from newborn specifc pathogen free piglets (SPF), just before colostrum uptake, generously provided by Anses Ploufragan (France), were used as negative controls (Table 1). SPF sows from Anses are originally delivered by cesarean section in germ free conditions. Then, sows and their piglets are routinely tested by ELISA (serology) and PCR assays against various pathogens (porcine circoviruses, infuenza viruses, Aujeszky disease virus, *Mycoplasma hyopneumoniae*, *Haemophilus parasuis*, *Actinobacillus pleuropneumoniae*, porcine reproductive and respiratory syndrome virus, *Pasteurella multocida*, *Bordetella bronchiseptica*, *Streptococcus suis* type 1 and 2, *Salmonella* spp. and others) to confrm their SPF status at Anses high containment pig research facilities.

Table 1 Information about the diferent pig farms assessed in the study (− negative, + positive)

ND: not documented.

^a Newborn piglets before colostrum uptake.

All the other tested sera were obtained during routine prophylactic monitoring from fve diferent pig farms $(A-E)$ all located in the West of France (Table 1). In three farms (A, B, and E) clinical signs such as coughing, sneezing, and high respiratory frequency were clearly identifed in most of the pigs. In one farm (D), faint clinical signs such as coughing were reported in some pigs.

To optimize the reading of every OD, sera were diluted 1/800 as validated from the dilution range analysis (Additional fle 1). ELISA to detect the presence of antibodies porcine reproductive and respiratory syndrome virus (PRRSV) (IDEXX Montpellier SAS, Montpellier, France) and *Mycoplasma hyopneumoniae* (IDEXX and Oxoid-ThermoFisher Scientific), two major porcine respiratory pathogens [7], had been performed previously to assess the status of the selected pig farms. Porcine infuenza is endemic in most of the French pig farms [8, 9] and the virus was either isolated, not sought or absent. Regarding *Actinobacillus pleuropneumoniae*, specifc lesions were sought and in one farm serology to all commonly circulating serotypes assessed. All the pigs were routinely followed by veterinarians for clinical signs of respiratory infection (coughing and increased respiratory frequency amongst others). To test cross-reactivity with BRSV, porcine sera were assessed with IDEXX RSV IgG Ab Test, a commercial ELISA developed to detect IgG targeting BRSV in bovine sera. The six porcine sera with the highest OD in our ELISA and the seven sera with lowest OD were used for the bovine ELISA. As positive and negative controls, bovine sera positive and negative for anti-RSV IgG, generously provided by large animal clinic (Dr Sebastien Assié, Oniris), were used. Then, the same bovine samples were tested in our next described anti-SOV ELISA.

Enzyme-linked immunosorbent assays

Swine orthopneumovirus specifc antibodies were detected using an ELISA with SOV N as target antigen. Optimal concentrations of the antigen and the enzyme conjugated secondary antibody were defned after testing diferent conditions as specifed in the recommendations for standardization and validation of ELISA assay [2]. ELISA plates (NUNC 96, ThermoFisher Scientific, Illkirch, France) were coated overnight at 4 °C with SOV N (15 μ g/mL) in carbonate buffer (0.1 M, pH 9.5, 100 μ L/ well). The plates were then washed twice for 5 min with phosphate-bufered saline (PBS) containing 1% Tween 20 (Sigma-Aldrich Chimie, Saint-Quentin Fallavier) (PBST) and blocked by an incubation with 130 μ L/well of 2% gelatin (Bio-Rad, Marnes-la-Coquette, France) in carbonate bufer (0.1 M, pH 9.5) for 30 min at 37 °C. After this incubation, the liquid was discarded and plates were washed twice with PBST. Then, $100 \mu L$ of each serum sample, serially diluted in PBST to dilution 1/800, was added (in duplicate) and incubated at 37 °C for 1 h. Subsequently, the plates were washed twice with PBST and incubated for 1 h at 37 \degree C with 100 µL/well of goat anti pig IgG conjugated to horseradish peroxidase (Goat anti Pig IgG (Fc): HRP ref AAI41P) (Bio-Rad) at 0.1 µg/mL diluted in PBST. Then, the plate was washed twice with PBST and twice with PBS. Substrate solution, TMB signal + (Bio-Rad) was subsequently added (100 μ L/well) and the plate was incubated at $22-27$ °C for 20 min. The reaction was stopped by the addition of 100 μ L H₂SO₄ 0.2 M to each well (Sigma-Aldrich Chimie). Optical densities (OD) were measured at 450 nm using a microplate reader (ThermoFisher Scientific Multiskan GO 1.01.10).

Results

Purifcation and characterization of recombinant SOV N protein

We previously developed a protocol to purify HRSV N protein as nanorings containing 10 or 11 N protomers and 70 or 77 bases in length RNA, respectively [6, 10]. HRSV P is composed of a N-terminal disordered region (residues 1–125), a central tetramerization domain (residues 126–160) and a C-terminal disordered region (residues $161-241$) [11]. The C-terminal region of HRSV P (PCT) fused to GST was found highly efficient for purifying RSV N from *E. coli*. In order to apply this technique to SOV, we aligned HRSV and SOV P protein sequences to defne the corresponding regions of SOV P. Tanks to sequence homologies between HRSV and SOV P, the SOV P region extending from amino acid residues 208 to 295 (MW \sim 10 kDa) was identified as the C-terminal disordered and N-binding region of P (Figure 1). This SOV PCT region was fused to GST in the pGEX-4T-3 vector and co-expressed in *E. coli* together with the pET-28-N vector. As shown in Figure 2, SOV N and GST-PCT were purifed to >95% homogeneity. SOV N, migrating with apparent MW of 43 kDa, as expected, was recovered as a soluble protein after thrombin cleavage of the GST-PCT/N complexes bound to glutathione-Sepharose beads.

When using a similar technique, HRSV N protein is recovered as rings containing either 10 or 11 N protomers and with a diameter of \sim 15–20 nm [6, 10]. To determine whether SOV N was also composed of nanorings, purifed complexes were analysed by size-exclusion chromatography on a Sephacryl S-200 column (GE Healthcare) and the collected fractions were analysed by SDS-PAGE and Coomassie blue staining. The first peak $(P1)$ eluted at 23 mL, with absorption detected at both 220, 260 and 280 nm, and contained exclusively the SOV N protein (Figure 3). Since the UV absorption was higher at 260 nm than 280 nm, these data indicated that RNA was present

in the N fraction. The size of this complex was estimated to be approximately 530 kDa, indicating that N was present as oligomers. The second peak (P2) only absorbed at 220 nm and contained the PCT fragment. Its apparent mass was comprised between 25 and 43 kDa, higher than its predicted mass of 10 kDa, presumably due to a markedly non-globular shape of the P fragment.

The SOV N protein purified by gel filtration was analysed by negative stain electron microscopy. A representative micrograph, shown in Figure 4, confrmed that SOV N was recovered as nanorings with a diameter of \sim 15 nm.

Detection of anti-pneumovirus antibodies in French swine herds using SOV N protein

The recombinant SOV N was then used to develop an ELISA in order to detect antibodies targeting pneumovirus N in some French pig farms. ELISA was optimized and the 1/800 dilution, still in the linear phase of the standard curve (Additional file 1) as recommended $[2]$, was ultimately selected. Indeed, the 1/400 dilution generated too many samples with very OD and was not further

used (Additional fle 2). Additional standard curves generated from subsequent samples with higher OD needed extremely high dilutions to linearize the signal and were not selected for following analyses (Additional fle 3).

Specifc pathogen free piglets before colostrum uptake were sero-negative for anti-pneumovirus N antibodies. On the contrary, most of the sera collected from pigs raised in fve diferent farms from the West of France that were routinely monitored for respiratory infectious diseases (see Table 1) showed positivity to various levels (Figure 5). Variations between pigs positive for anti-pneumovirus N antibodies was signifcant with OD ranging between 0.47 and 3.52 (dilution $1/800$). Three sera presented very high OD values and ideally should have been further diluted, at least two folds, before being tested. Interestingly, a herd (C) negative for PRRSV, without *A. pleuropneumoniae* specifc lesions, and presenting mild respiratory symptoms was positive for anti-pneumovirus N antibodies (Figure 5 and Table 1). However, infuenza virus status was not determined for this farm (Figure 5).

Cross reactivity tests based on porcine sera tested with the BRSV ELISA and bovine sera tested with our pig ELISA showed absence of cross-reactivity of the antibodies. Indeed, porcine sera tested with the BRSV ELISA could be considered negative for anti-BRSV antibodies (see Figure 6) and strongly positive bovine sera for BRSV had OD values < 0.005 when tested with our new ELISA.

Discussion

The presence of pneumoviruses in swine is poorly documented. Recently a newly discovered swine pneumovirus (SOV) was identifed by metagenomic sequencing of pooled nasal swabs in feral swine in USA [4]. Sequence comparison with other members of the *Pneumoviridae* family showed that SOV is closely related to PVM and CPV. For example, amino acid sequence identities between SOV and other pneumoviruses N proteins are of 97.5% for PVM, 97.5% for CPV, 59.8% for HRSV, 60% for BRSV, 45.7% for HMPV, and 43.3% for AMPV, respectively. However, SOV has not been isolated yet and it is completely unknown whether this virus is pathogenic.

Although a study performed by Allan et al. in 1998 showed that 41% of pigs sera from 61 herds in Northern Ireland were reactive with BRSV antigens [5], thus suggesting the presence of pneumovirus in swine, this kind of study has not been carried out in other European countries yet. The aim of this work was to investigate the presence of pneumovirus in French swine. Among pneumovirus proteins, the N protein is highly conserved between strains and, as an example, for HRSV it was shown to be highly immunogenic either by natural infection $[12]$ or by administration $[13-18]$. RSV N protein \vee 76 5 $\overline{4}$ 3 $\overline{2}$ $\overline{1}$

 N_M

 $OD_{260/280} = 1.4$

PCT

4 N

12 15 19 23 27 31 35 38 42 46 50 54 58

Elution volume (mL) -280 nm -260 nm -220 nm 6 000

5 0 0 0

4 000 을
3 000 원

2 0 0 0

1 0 0 0

 $\overline{0}$

 $\overline{\mathsf{A}}$

 A_{280} and A_{260} (mAu)

B

 $95₁$ 72 55

 36_b 28

 $17 \triangleright$

 10_b

19 21 23

 $1,200$

 1000

800

600

400

200

 $\overline{0}$

 Ω $\overline{4}$ 8

has also been used to develop RSV specifc ELISAs [12– 18]. Using the recently published sequence of SOV, we engineered and purifed recombinant and soluble SOV N protein from *E. coli*. Like observed previously with HRSV a 0.22 µm pore-size flter and run on a Sephacryl S200 column and fractions of 1 mL were collected. The following size markers (GE Healthcare) were used to calibrate the column (mass in parentheses): 1, ribonuclease A (13 700); 2, chymotrypsinogen A (20 200); 3, ovalbumin (47 200); 4, albumin (61 000); 5, catalase (232 000); 6, ferretin (440 000); 7, thyroglobulin (699 000). V, Void volume; T, total volume of the column. **B** The indicated fractions were analyzed by SDS-PAGE as described in Figure 2.

Figure 3 Elution profle of the PCTD+N complexes. A Absorbances were monitored at 280 nm (blue line), 260 nm (red line) and 220 nm (gray line). Samples (3 mL) were fltered through

Elution volume of gel filtration (mL)

25

27

[6], SOV N protein produced in bacteria forms soluble nanorings containing nucleic acids that can be purifed to >95% homogeneity by using the C-terminal region of SOV P fused to GST. Like for HRSV [10], the SOV nanorings were composed of two major populations with an average diameter of $~15$ nm, which correspond to the **recombinant SOV N after purifcation by gel fltration.** Scale bar, 100 nm.

diameter of the left-handed helical nucleocapsid of pneumoviruses [10, 19, 20]. Although we have no explanation for the presence of nanorings only and the absence of helical structures in this system, these nanorings must be formed thanks to the elasticity of N oligomers, the absence of other factors such as full length P, and N–N interactions occurring after one helix turn and closing the ring structure.

Swine orthopneumovirus N nanorings were then used to develop an anti-pneumovirus N ELISA. Our results revealed indirectly a signifcant circulation of a pneumovirus between pigs within selected pig farms in the West of France and an absence of anti-pneumovirus antibodies

in SPF piglets. Results in these SPF piglets could be used to estimate the cut-off value for negativity around OD 0.5 even if it must be further confrmed by future research with experimental inoculation of the virus to fully naïve pigs. Moreover, seronegativity of SPF piglets is also an interesting observation as it shows an absence of crossreactivity of our ELISA test to porcine plasmatic proteins. Then, the absence of cross-reactivity with BRSV allowed us to exclude the potential circulation of a bovine pneumovirus in pigs. However cross-reactivity with other pneumoviruses should also be tested. Indeed, pneumovirus N proteins present strong similarities between pneumoviruses. Our cross-reactivity test results could seem contradictory with the study from Allan et al. [5]. This discrepancy might be explained by the use of various BRSV ELISA (diferences in the conformation of the selected antigen and sensitivity for instance). The detection of anti-pneumovirus N antibodies in one farm (C) negative for PRRSV, under vaccination control for *M. hyopneumoniae*, and most probably negative for *A. pleuropneumoniae* but still presenting respiratory symptoms might suggest a potential pathogenicity of SOV in pigs, in association or not with other member of the porcine respiratory complex (PRC). The situation in farms A and B, showing similar respiratory pathogen profle to that of farm C but where infuenza virus had been detected before might also support to some extent that hypothesis.

However, since many other pathogens are involved in the PRC and because of the absence of clinical data collected for every individual pig in our study, there is an urgent need for further research before being able to formulate strong conclusions regarding SOV potential pathogenicity.

In summary, this work is the frst one showing that a pneumovirus is present or had circulated in some French pig farms. Future prospects will be needed to give a more complete image of the percentage of positive pigs in French farms. However, it is currently completely unknown whether SOV is pathogenic or not for pigs. Future isolation of SOV and experimental animal infections are needed to allow deep characterization of the porcine pneumovirus and the determination of its pathogenicity in various conditions. SOV could also represent a new animal model for pneumovirus infection [21].

Additional fles

[Additional fle 1.](https://doi.org/10.1186/s13567-018-0615-x) Serum dilution range of the SOV N ELISA. Serum dilution 1/800 were ultimately selected for antibody detection.

[Additional fle 2.](https://doi.org/10.1186/s13567-018-0615-x) SOV N ELISA results using dilution 1/400. Optical density (OD) was varying between herds with some specifc pathogen free piglets before colostrum uptake staying free of anti-pneumovirus antibodies.

[Additional fle 3.](https://doi.org/10.1186/s13567-018-0615-x) Standard curves generated from highest OD samples (green and brown lines) were compared to the selected standard curve (blue line). Dilutions of the negative standard is presented in red.

Abbreviations

AMPV: avian metapneumovirus; CPV: canine pneumovirus; ELISA: enzyme linked immuno sorbent assay; GST: glutathione-*S*-transferase; HMPV: human metapneumovirus; PVM: pneumonia virus of mice; MW: molecular weight; N: nucleoprotein; OD: optical density; P: phosphoprotein; PCT: phosphoprotein C-terminal region; PRRSV: porcine reproductive and respiratory syndrome virus; RSV: respiratory syncytial virus; SOV: swine orthopneumovirus; TBE: Tris– borate–EDTA buffer.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

JFE supervised the project and conceived part of the experiments. FM supervised ELISA development. IG, FM, FR, CAR and JFE analysed the data and drafted the manuscript. CH carried out most of the experiments related to the ELISA development. CAR, CH, DM, VN, and IG performed part of the experiments. All authors read and approved the fnal manuscript.

Acknowledgements

We acknowledge the usage of the electron microscope of the dedicated platform of the Grenoble Instruct center (ISBG; UMS 3518 CNRS-CEA-UGA-EMBL) with support from FRISBI [Agence Nationale de la Recherche (ANR)] (ANR-10-INSB-05-02) and GRAL (ANR-10-LABX-49-01) within the Grenoble Partnership for Structural Biology (PSB). The electron microscope facility is supported by the *Rhône*-*Alpes* Region, the *Fondation pour la Recherche Médicale* (FRM), the *fonds* FEDER, the *Centre National de la Recherche Scientifque* (CNRS), the *Commissariat à l'Énergie Atomique et aux Energies Alternatives* (CEA), the University of Grenoble Alpes, EMBL, and the GIS-*Infrastructures en Biologie*

Santé et Agronomie (IBISA). FM is supported by an establishment grant from the *Région Pays de la Loire* (RFI Food for tomorrow-Cap aliment). This lab work was carried out with the fnancial support of the regional programme "Food for Tomorrow/Cap Aliment; Research, Education and Innovation in *Pays de la* Loire", which is supported by the French Region *Pays de la Loire* and the European Regional Development Fund (FEDER). Thanks also to Prof. Alain Chauvin and Daniel Hogan for their helpful comments.

Author details

¹ Unité de Virologie et Immunologie Moléculaires, INRA, Université Paris-Saclay, 78350 Jouy-en-Josas, France.² BIOEPAR, INRA, Oniris, Université Bretagne Loire, 44307 Nantes, France.³ CNRS, CEA, IBS, University of Grenoble Alpes, 38000 Grenoble, France. 4 Porc.Spective Swine Vet Practice, Chêne Vert Conseil Veterinary Group, ZA de Gohélève, 56920 Noyal‑Pontivy, France.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional afliations.

Received: 1 October 2018 Accepted: 29 November 2018

References

- 1. Afonso CL, Amarasinghe GK, Banyai K, Bao Y, Basler CF, Bavari S, Bejerman N, Blasdell KR, Briand FX, Briese T, Bukreyev A, Calisher CH, Chandran K, Cheng J, Clawson AN, Collins PL, Dietzgen RG, Dolnik O, Domier LL, Dur‑ rwald R, Dye JM, Easton AJ, Ebihara H, Farkas SL, Freitas-Astua J, Formenty P, Fouchier RA, Fu Y, Ghedin E, Goodin MM et al. (2016) Taxonomy of the order *Mononegavirales*: update 2016. Arch Virol 161:2351–2360
- 2. Wright PF, Nilsson E, Van Rooij EM, Lelenta M, Jeggo MH (1993) Standardisation and validation of enzyme-linked immunosorbent assay techniques for the detection of antibody in infectious disease diagnosis. Rev Sci Tech 12:435–450
- 3. Rima B, Collins P, Easton A, Fouchier R, Kurath G, Lamb RA, Lee B, Maisner A, Rota P, Wang L, Ictv Report Consortium (2017) ICTV virus taxonomy profle: Pneumoviridae. J Gen Virol 98:2912–2913
- 4. Hause BM, Padmanabhan A, Pedersen K, Gidlewski T (2016) Feral swine virome is dominated by single-stranded DNA viruses and contains a novel *Orthopneumovirus* which circulates both in feral and domestic swine. J Gen Virol 97:2090–2095
- 5. Allan GM, McNeilly F, Walker IW, Young JA, Fee S, Douglas AJ, Adair BM (1998) Serological evidence for pneumovirus infections in pigs. Vet Rec 142:8–12
- 6. Tran TL, Castagne N, Bhella D, Varela PF, Bernard J, Chilmonczyk S, Berkenkamp S, Benhamo V, Grznarova K, Grosclaude J, Nespoulos C, Rey FA, Eleouet JF (2007) The nine C-terminal amino acids of the respiratory syncytial virus protein P are necessary and sufficient for binding to ribonucleoprotein complexes in which six ribonucleotides are contacted per N protein protomer. J Gen Virol 88:196–206
- 7. Fablet C, Marois-Crehan C, Simon G, Grasland B, Jestin A, Kobisch M, Madec F, Rose N (2012) Infectious agents associated with respiratory diseases in 125 farrow-to-fnish pig herds: a cross-sectional study. Vet Microbiol 157:152–163
- 8. Cador C, Andraud M, Willem L, Rose N (2017) Control of endemic swine fu persistence in farrow-to-fnish pig farms: a stochastic metapopulation modeling assessment. Vet Res 48:58
- 9. Simon-Grife M, Martin-Valls GE, Vilar MJ, Busquets N, Mora-Salvatierra M, Bestebroer TM, Fouchier RA, Martin M, Mateu E, Casal J (2012) Swine influenza virus infection dynamics in two pig farms; results of a longitudinal assessment. Vet Res 43:24
- 10. Tawar RG, Duquerroy S, Vonrhein C, Varela PF, Damier-Piolle L, Castagne N, MacLellan K, Bedouelle H, Bricogne G, Bhella D, Eleouet JF, Rey FA (2009) Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science 326:1279–1283
- 11. Pereira N, Cardone C, Lassoued S, Galloux M, Fix J, Assrir N, Lescop E, Bontems F, Eleouet JF, Sizun C (2017) New insights into structural disorder in human respiratory syncytial virus phosphoprotein and implications for binding of protein partners. J Biol Chem 292:2120–2131
- 12. Zhang Y, Brooks WA, Goswami D, Rahman M, Luby SP, Erdman DD (2014) A duplex recombinant viral nucleoprotein microbead immunoassay for simultaneous detection of seroresponses to human respiratory syncytial virus and metapneumovirus infections. J Virol Methods 206:55–62
- 13. Roux X, Dubuquoy C, Durand G, Tran-Tolla TL, Castagne N, Bernard J, Petit-Camurdan A, Eleouet JF, Rifault S (2008) Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus. PLoS One 3:e1766
- 14. Rifault S, Meyer G, Deplanche M, Dubuquoy C, Durand G, Soulestin M, Castagne N, Bernard J, Bernardet P, Dubosclard V, Bernex F, Petit-Camurdan A, Deville S, Schwartz-Cornil I, Eleouet JF (2010) A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus. Vaccine 28:3722–3734
- 15. Blodorn K, Hagglund S, Fix J, Dubuquoy C, Makabi-Panzu B, Thom M, Karlsson P, Roque JL, Karlstam E, Pringle J, Eleouet JF, Rifault S, Taylor G, Valarcher JF (2014) Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies. PLoS One 9:e100392
- 16. Herve PL, Raliou M, Bourdieu C, Dubuquoy C, Petit-Camurdan A, Bertho N, Eleouet JF, Chevalier C, Rifault S (2014) A novel subnucleocapsid nanoplatform for mucosal vaccination against infuenza virus that targets the ectodomain of matrix protein 2. J Virol 88:325–338
- 17. Herve PL, Descamps D, Deloizy C, Dhelft V, Laubreton D, Bouguyon E, Boukadiri A, Dubuquoy C, Larcher T, Benhamou PH, Eleouet JF, Bertho N, Mondoulet L, Rifault S (2016) Non-invasive epicutaneous vaccine against respiratory syncytial virus: preclinical proof of concept. J Control Release 243:146–159
- 18. Herve PL, Deloizy C, Descamps D, Rameix-Welti MA, Fix J, McLellan JS, Eleouet JF, Riffault S (2017) RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine. Nanomedicine 13:411–420
- 19. Bakker SE, Duquerroy S, Galloux M, Loney C, Conner E, Eleouet JF, Rey FA, Bhella D (2013) The respiratory syncytial virus nucleoprotein-RNA complex forms a left-handed helical nucleocapsid. J Gen Virol 94:1734–1738
- 20. Liljeroos L, Krzyzaniak MA, Helenius A, Butcher SJ (2013) Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A 110:11133–11138
- 21. Meurens F, Summerfeld A, Nauwynck H, Saif L, Gerdts V (2012) The pig: a model for human infectious diseases. Trends Microbiol 20:50–57

Ready to submit your research? Choose BMC and benefit from:

- **•** fast, convenient online submission
- **•** thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- **•** gold Open Access which fosters wider collaboration and increased citations
- **•** maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

